|
Actiq News is an EIN News Service for health professionals. Constantly updated news and information about health.
- Covidien Receives FDA Approval for Oral Transmucosal Fentanyl Citrate Product 2 Nov 2009 21:36 GMT
... Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New ... is a generic alternative to the branded ACTIQ . It is a solid formulation of ... this FDA approval and to introduce this treatment option to meet patients' needs.” Covidien expects ...
- Mallinckrodt painkiller gets FDA OK 2 Nov 2009 14:32 GMT
... inside the cheek for pain relief. It is a generic alternative to the branded ACTIQ. Covidien said Friday that it expects to launch the drug in the U.S. in early 2010. , is led by President Timothy Wright. Covidien had ...
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients... 3 Nov 2009 00:35 GMT
... today announced that the November issue of has ... These data were part of the new drug application approved by the FDA in 2007. This ... in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and ...
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder 2 Nov 2009 21:50 GMT
... Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients ... These data were part of the new drug application approved by the FDA in 2007. This ... in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and ...
- QUICK TAKE: CEPHALON INC (CEPH) 5 Nov 2009 14:42 GMT
... target central nervous system (CNS) disorders, pain treatments, and oncology (cancer). The star product over ... for about half of sales. Other significant drugs in the portfolio are Fentora and Actiq (the former a replacement for the latter), ...
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma 5 Nov 2009 16:31 GMT
... Pivotal Data Published in the Journal Cancer Demonstrate ... progressed during or within six months of treatment with rituximab. Results of this study, which ... indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and ...
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non 5 Nov 2009 16:32 GMT
... Pivotal Data Published in the Journal Cancer Demonstrate ... progressed during or within six months of treatment with rituximab. Results of this study, which ... indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and ...
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in R 5 Nov 2009 16:37 GMT
... Pivotal Data Published in the Journal Cancer Demonstrate ... progressed during or within six months of treatment with rituximab. Results of this study, which ... indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and ...
- Pivotal Data Published in the Journal Cancer Demonstrate that... 5 Nov 2009 17:18 GMT
... FRAZER, Pa., Nov. 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. ... progressed during or within six months of treatment with rituximab. Results of this study, which ... indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and ...
- Journal Cancer Publishes Pivotal Study of TREANDA in Patients with in Relapsed Indolent NHL 5 Nov 2009 19:17 GMT
... Journal Cancer Publishes Pivotal Study of TREANDA in ... progressed during or within six months of treatment with rituximab. Results of this study, which ... indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and ...
- Cephalon, Inc. to Webcast R&D Day 4 Nov 2009 19:14 GMT
... FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. ... on two investigational medications, Lupuzor(TM), for the treatment of systemic lupus erythematosus and Ception Therapeutics, ... in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and ...
- Cephalon, Inc. to Webcast R&D Day 4 Nov 2009 19:31 GMT
... FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. ... on two investigational medications, Lupuzor(TM), for the treatment of systemic lupus erythematosus and Ception Therapeutics, ... in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and ...
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma (PRN) 5 Nov 2009 16:35 GMT
... is an international biopharmaceutical company dedicated to the discovery, development and ... economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more ...
- Cephalon, Inc. to Webcast R&D Day (PRN) 4 Nov 2009 19:30 GMT
... is an international biopharmaceutical company dedicated to the discovery, development and ... economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more ...
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder (PRN) 2 Nov 2009 21:50 GMT
... is an international biopharmaceutical company dedicated to the discovery, development and ... economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
bbc.co.uk:
healthday.com:
reuters.com: